<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inactivation of the TP53 (p53) pathway by TP53 mutations is one of key steps in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>TP53 also plays an important role in cellular energy metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that TP53-altered <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells might behave aggressively independent of energy balance, while progression of TP53-intact cells might depend on excess energy balance </plain></SENT>
<SENT sid="3" pm="."><plain>Utilizing a database of 1,060 colon and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> patients in two prospective cohort studies, we evaluated TP53 expression by immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>Among 1,060 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, 457 (43%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were positive for TP53 </plain></SENT>
<SENT sid="5" pm="."><plain>Cox proportional hazards model was used to compute mortality hazard ratio (HR), adjusting for clinical and tumoral features, including microsatellite instability, the CpG island methylator phenotype, LINE-1 methylation, KRAS, BRAF and PIK3CA </plain></SENT>
<SENT sid="6" pm="."><plain>TP53 positivity was not significantly associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival in univariate analysis with HR of 1.16 [95% confidence interval (CI)=0.92-1.45], which became significant after stage adjustment (multivariate HR=1.30; 95% CI=1.02-1.65) </plain></SENT>
<SENT sid="7" pm="."><plain>Notably, we found a possible modifying effect of patient's body mass index (BMI) on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> TP53 </plain></SENT>
<SENT sid="8" pm="."><plain>In non-<z:mp ids='MP_0001261'>obese</z:mp> patients (BMI&lt;30 kg/m2), TP53 positivity was associated with shorter <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival (multivariate HR=1.53; 95% CI=1.17-2.00), while TP53 positivity was not significantly associated with survival among <z:mp ids='MP_0001261'>obese</z:mp> patients (BMIâ‰¥30 kg/m2) </plain></SENT>
<SENT sid="9" pm="."><plain>Effect of TP53 positivity on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival significantly differed by BMI (pinteraction=0.0051) </plain></SENT>
<SENT sid="10" pm="."><plain>The adverse effect of <z:hpo ids='HP_0001513'>obesity</z:hpo> on patient mortality was limited to TP53-negative patients </plain></SENT>
<SENT sid="11" pm="."><plain>These molecular pathological epidemiology data may support a dual role of TP53 alterations in cell-cycle deregulation and cell autonomy with respect to energy balance status </plain></SENT>
</text></document>